EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Outcomes of Insulin Glargine U300 on Glycemic Control and Hypoglycemia: A Retrospective Observational Study

Gökçen Güngör Semiz iD, Mehmet Çağrı Ünal iD, İsmail Selimoğlu, Sıla Kalender, Ege Erbay, Mehmet Emin Arayici iD, Abdurrahman Çömlekçi, Serkan Yener, Tevfik Demir

Journal of Clinical Medicine · 05.05.2026 · 15 (9) · 3529

DOI: 10.3390/jcm15093529 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 05.05.2026. Verfasst von Gökçen Güngör Semiz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, 35330 İzmir, Türkiye. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Insulin glargine U300 (IGlarU300) is a second-generation, long-acting insulin analog designed to provide a more stable pharmacokinetic profile compared to insulin glargine U100. However, long-term real-world data reflecting its long-term impact on glycemic control and hypoglycemia across diverse populations remain limited. This study evaluated the 24-month clinical outcomes of transitioning to IGlarU300 in a real-world setting.

Methods

This retrospective, single-center, observational study enrolled patients with type 1 (T1DM) or type 2 diabetes mellitus (T2DM) who transitioned to IGlarU300 between 2017 and 2021. HbA1c levels, body weight, insulin doses, and hypoglycemia rates were evaluated at baseline and up to 24 months.

Results

A total of 242 patients (T1DM: n = 68, T2DM: n = 174) were analyzed. HbA1c levels significantly declined at all follow-up points compared to baseline (mean change at 12 months: −0.85% [95% CI: −1.24 to −0.47%]; p < 0.001]). No significant change in total insulin dose was observed over the one-year follow-up; however, improved glycemic control led to a significant reduction in oral antidiabetic medication use, reflecting successful treatment simplification and a decrease in polypharmacy burden (mean change: -0.50 [95% CI: −0.70 to −0.30]; p < 0.001). Notably, both severe and mild hypoglycemia episodes showed significant reductions (p = 0.010 and p = 0.019, respectively). Switching to IGlarU300 was associated with sustained improvements in glycemic control and a reduction in hypoglycemia rates.

Conclusions

These findings suggest that IGlarU300 may be an effective clinical option for optimizing metabolic outcomes, though further controlled studies are warranted to confirm these observational results.

Schlagwörter

Stichwörter der Autor:innen

basal insulin analogsdiabetes mellitusmetabolic controloral antidiabetic agentsreal-world evidence

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, 35330 İzmir, Türkiye.
  • Department of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, 35330 Izmir, Türkiye.
  • Department of Biostatistics and Medical Informatics Faculty of Medicine, Dokuz Eylül University, 35340 İzmir, Türkiye.
  • Department of Public Health, Faculty of Medicine, Dokuz Eylül University, 35330 İzmir, Türkiye.

ORCID-Profile: Gökçen Güngör Semiz, Mehmet Çağrı Ünal, Mehmet Emin Arayici

Zitieren

APA

Güngör Semiz, G., Ünal, M. Ç., Selimoğlu, İ., Kalender, S., Erbay, E., Arayici, M. E., Çömlekçi, A., Yener, S., & Demir, T. (2026). Clinical Outcomes of Insulin Glargine U300 on Glycemic Control and Hypoglycemia: A Retrospective Observational Study. Journal of Clinical Medicine, 15(9), 3529. https://doi.org/10.3390/jcm15093529

Vancouver

Güngör Semiz G, Ünal MÇ, Selimoğlu İ, Kalender S, Erbay E, Arayici ME, et al. Clinical Outcomes of Insulin Glargine U300 on Glycemic Control and Hypoglycemia: A Retrospective Observational Study. Journal of Clinical Medicine. 2026;15(9):3529. doi:10.3390/jcm15093529

BibTeX
@article{GngrSemiz2026,
  author = {Güngör Semiz, Gökçen and Ünal, Mehmet Çağrı and Selimoğlu, İsmail and Kalender, Sıla and Erbay, Ege and Arayici, Mehmet Emin and Çömlekçi, Abdurrahman and Yener, Serkan and Demir, Tevfik},
  title = {Clinical Outcomes of Insulin Glargine U300 on Glycemic Control and Hypoglycemia: A Retrospective Observational Study},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {9},
  pages = {3529},
  doi = {10.3390/jcm15093529}
}
Kostenlos starten →